Lilly

Roche Insists Amylin Obesity Drug Still Valuable for Patients Who ‘Don’t Want Side Effects’

WHCD Shooting, DOJ Ends Powell Probe, Musk Vs. Altman and More in Morning Squawk

As Millions Lose Weight on GLP-1s, They're Starting to Turn to Retailers to Refresh Their Wardrobes

Lilly’s Foundayo Reaches 1,390 Patients in First Week, Trailing Novo’s Oral Wegovy Launch

Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder

Wall Street Slides as S&P 500 Dips 0.1% and Brent Falls to $95 Amid U.S.-Iran Cease‑fire Talks

Amazon Launches GLP‑1 Weight‑Loss Program, Targeting $25‑Per‑Month Market

5 FDA Decisions to Watch in the First Quarter of 2026

Medicare Launches $50 GLP‑1 Bridge Pilot for Weight‑Loss Drugs

Isomorphic Labs Raises $2.1 B to Expand AI-Driven Drug Discovery Platform

Omada Health Reports 42% Revenue Growth in Q1 2026 Earnings

Keep an Eye on These 15 Biotech Companies in 2026 

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall

AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

Options Traders Pick Up Pharma Stock After Eli Lilly Buyout

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Semaglutide Cuts Cardiac Risk 20% and Retatrutide Hits All Diabetes Endpoints

Trump's Obesity Drug Plan for Medicare Would Cost Insurers Billions

STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More

Novartis Breaks Ground on San Diego Biomedical R&D Site

4 Spaces Primed for the Next Wave of Gene Therapies

STAT+: Novo Nordisk’s Less-Bad News on Its Wegovy Pill Boosts Earnings and Share Price

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Transcript

Biotech in 2025: A Retrospective 

FDA Approves Eli Lilly’s Foundayo, Pitting First Oral Obesity Pill Against Novo Nordisk’s Wegovy

Small And Mid-Sized Startup Purchases Are Still Well Below The 2021 Peak

Eli Lilly’s Jaypirca Secures Fourth Phase III Win in CLL, Paving Way for Label Expansion

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

Thursday Links: A Job in a System

High-Dose Wegovy Debuts at $399 for Self-Paying Patients

STAT+: Finally Cracking KRAS as a Druggable Target

Sun Pharma to Acquire Organon for $11.75 Bn, Marking India's Largest Overseas Pharma Deal

European Regulators Approve First‑In‑Human GLP‑1 Gene Therapy Trial for Fractyl Health

Pfizer’s Early Metsera Data Leaves Analysts Wanting More

Eli Lilly Raises $9 Billion in Record Investment‑Grade Bond Offering to Finance Acquisitions

AI, Gene Therapies Drive Market Trends in Eye Care

TerraPower Commits $450M to Build Radioisotope Production Plant

Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes

Entera Announces First Quarter 2026 Financial Results and Updates Across Its Oral Peptide Programs

Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review

Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4

White House Adds Generic Drugs to Direct-to-Consumer TrumpRx Site

Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B

GLP-1s and Anhedonia: The Death of Dopamine Snacking

Tradipitant

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

FDA Proposes Excluding Novo, Lilly Weight Loss Drugs From Bulk Compounding List in Win for the Companies

Syremis Therapeutics Raises $165M in Series A Financing

The Next Fed Chair Has Crypto Exposure in His Portfolio. Here Are the Details

Eli Lilly to Acquire Ventyx Biosciences for $1.2B

Eli Lilly Inks $2.25B AI-Driven Enzyme Partnership with Profluent

Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly

QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures

Eli Lilly to Acquire CrossBridge Bio for up to $300M

Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3B

Sanegene Bio Secures Over $110M in Series B Funding

Eli Lilly Acquires Kelonia Therapeutics for $3.25B Upfront, up to $7B Total

Excelsior Sciences Secures $95M Series A Funding Led by Deerfield, Khosla and Sofinnova

Eli Lilly to Acquire Engage Biologics for Up to $202M

Eli Lilly to Acquire Ventyx for $1.2B

Eli Lilly Commits $2.75B to Insilico Medicine for AI‑discovered Drug Candidates

Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal

Eli Lilly Announces Acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics

Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion